These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21775746)

  • 1. Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Brandi G; Biasco G; Tavolari S
    J Natl Cancer Inst; 2011 Aug; 103(16):1278. PubMed ID: 21775746
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
    Katsios C; Ziogas DE; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
    Bass A
    J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
    [No Abstract]   [Full Text] [Related]  

  • 5. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
    Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
    Hess LM; Carter G; Smolen L; Bowman L; von Hohnhorst P; Seagle C
    J Natl Cancer Inst; 2014 Feb; 106(2):djt370. PubMed ID: 24381069
    [No Abstract]   [Full Text] [Related]  

  • 8. BRAF testing in advanced colorectal cancer: is it ready for prime time?
    Phillips B; Kalady M; Kim R
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):437-44. PubMed ID: 20733556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
    Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M
    Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR signalling and oncogenic pathway signature in colorectal cancer.
    Sahin IH; Oktay AA
    Gut; 2013 Nov; 62(11):1670. PubMed ID: 23532175
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond KRAS: a new approach in metastatic colorectal cancer.
    Winder T; Lenz HJ
    Lancet Oncol; 2010 Aug; 11(8):706-7. PubMed ID: 20619738
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
    Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
    J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
    Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells.
    Xavier CP; Lima CF; Preto A; Seruca R; Fernandes-Ferreira M; Pereira-Wilson C
    Cancer Lett; 2009 Aug; 281(2):162-70. PubMed ID: 19344998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.